Methods of Treating a Tauopathy
AssigneeiPierian, Inc.
InventorsIrene Griswold-Prenner, Nancy E. Stagliano, Vu Cao Dang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.
Claims31
-62. (canceled)
A method of monitoring progression of a tauopathy in an individual, the method comprising:
- a) determining a first level of a Tau polypeptide in a biological sample obtained from the individual at a first time point;
- b) determining a second level of a Tau polypeptide in a biological sample obtained from the individual at a second time point;
- and
- c) comparing the second level of Tau with the first level of Tau, wherein said determining comprises:
- i) contacting the biological sample with an antibody comprising a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO:37 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO:41;
- and
- ii) quantitating binding of the antibody to Tau polypeptide present in the sample.
A method of detecting a Tau polypeptide in a living individual in vivo, the method comprising:
- a) administering to the individual an antibody comprising a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO:37 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO:41;
- and
- b) detecting binding of the antibody to tau polypeptide in a brain tissue in the individual using an imaging method.
An in vitro method of detecting a Tau polypeptide in a biological sample obtained from an individual, the method comprising:
- a) contacting the biological sample with an antibody competes for binding to an epitope within the N-terminal region of Tau with an antibody that comprises:
- i) light chain complementarity-determining regions (CDRs) of an antibody depicted in FIG. 1B;
- and heavy chain CDRs of an antibody depicted in FIG. 1A;
- or
- ii) light chain CDRs of an antibody depicted in FIG. 2B;
- and heavy chain CDRs of an antibody depicted in FIG. 2A;
- and
- b) detecting binding of the antibody to Tau polypeptide present in the sample.
A method of reducing the level of Aβ40 and/or Aβ42 in a neuronal cell and/or extracellular fluid in an individual, the method comprising administering to the individual:
- a) an effective amount of an antibody comprising a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO:37 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO:41;
- or
- b) a pharmaceutical composition comprising the antibody.
(canceled)
(canceled)
A method of determining the amount of extracellular Tau (eTau) unbound to an anti-eTau antibody in a sample of cerebrospinal fluid (CSF) or interstitial fluid (ISF) obtained from a subject undergoing therapy with the anti-eTau antibody, the method comprising:
- a) contacting an immobilized antibody with a sample of CSF or ISF obtained from the subject,
- wherein the immobilized antibody comprises a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO:37 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO:41, said contacting being under conditions suitable for binding of the unbound eTau to the immobilized antibody;
- and
- b) determining the amount of eTau bound to the immobilized antibody, wherein the amount of eTau bound to the immobilized antibody is an indication of the amount of eTau unbound to the anti-Tau antibody in the sample.
-84. (canceled)
(canceled)
-93. (canceled)
A nucleic acid or nucleic acids encoding an antibody comprising a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO:37 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO:41.
Dependencies are inferred from the claim text.